A T Van Oosterom

Author PubWeight™ 44.16‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997 1.54
2 Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans. Drug Metab Dispos 1995 1.39
3 Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol 1995 1.18
4 Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996 1.16
5 Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study. Br J Cancer 1995 1.16
6 Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 2005 1.07
7 A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998 1.05
8 Alkaline phosphatase isoenzyme patterns in malignant disease. Clin Chem 1992 1.04
9 Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997 0.98
10 Soft tissue sarcoma in adults. Curr Opin Oncol 1999 0.98
11 Quality control in multicentric clinical trials. An experience of the EORTC Gynecological Cancer Cooperative Group. Eur J Cancer 2000 0.93
12 The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol Oncol 1988 0.92
13 Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995 0.91
14 Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study. Eur J Cancer Clin Oncol 1983 0.91
15 Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Microvasc Res 1996 0.89
16 Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Res Treat 1997 0.88
17 Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 2006 0.86
18 The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anticancer Drugs 2002 0.84
19 Cooperative studies of systemic chemotherapy. A review of the work of the EORTC Urological Group and of the Yorkshire Urological Cancer Research Group (YUCRG). Cancer Chemother Pharmacol 1983 0.84
20 Pulmonary toxicity and bleomycin. Lancet 1994 0.83
21 Chemotherapy administration and data collection in an EORTC collaborative group--can we trust the results? Eur J Cancer 1993 0.83
22 In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs 1997 0.83
23 The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. Semin Oncol 1990 0.83
24 Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study. Eur J Cancer Clin Oncol 1982 0.82
25 Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density. Microvasc Res 1997 0.82
26 Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients. Br J Clin Pharmacol 1999 0.81
27 Soft tissue sarcoma in adults. Curr Opin Oncol 1997 0.81
28 Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b. J Natl Cancer Inst 1997 0.81
29 Chondrosarcoma and other rare bone sarcomas. Curr Opin Oncol 1991 0.81
30 Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions. Ann Oncol 2003 0.81
31 Combination chemotherapy with cis-diammine-dichloro-platinum, vinblastine, and bleomycin in advanced testicular non-seminoma. Lancet 1979 0.81
32 Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. Am J Clin Oncol 2000 0.81
33 The treatment of advanced ovarian carcinoma (II): interval reassessment operations during chemotherapy. Gynecol Oncol 1988 0.79
34 Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil. Pharm Weekbl Sci 1988 0.79
35 Predictive testing in cancer chemotherapy. II. In vitro. Pharm Weekbl Sci 1985 0.79
36 Sternal resection for primary presternal and retrosternal mediastinal liposarcoma. Eur J Cardiothorac Surg 1996 0.79
37 EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents. Eur J Cancer 1991 0.78
38 Hodgkin's disease in a patient with Von Hippel-Lindau disease. A case report. Acta Clin Belg 2000 0.78
39 Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 1999 0.78
40 Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts. Biochem Pharmacol 1996 0.78
41 The human tumour colony-forming assay using fresh specimens. Neth J Med 1986 0.78
42 In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour. J Cancer Res Clin Oncol 1993 0.77
43 Resistance patterns between cis-diamminedichloroplatinum(II) and ionizing radiation. Cancer Res 1991 0.77
44 The role of ifosfamide in the treatment of sarcomas. Semin Oncol 1989 0.77
45 Partitioning of ifosfamide and its metabolites between red blood cells and plasma. J Pharm Sci 1996 0.76
46 Activated oxazaphosphorines are transported predominantly by erythrocytes. Ann Oncol 1997 0.76
47 Multivariate analysis of prognostic variables in patients with disseminated non-seminomatous testicular cancer: results from an EORTC multi-institutional phase III study. Int J Androl 1987 0.76
48 Diagnosis and treatment of soft tissue sarcomas in adults. Curr Opin Oncol 1995 0.76
49 Response criteria phase II/phase III invasive bladder cancer. Prog Clin Biol Res 1986 0.76
50 CA 125 and TPA as markers in ovarian carcinoma. Neth J Med 1985 0.75
51 Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. Breast Cancer Cooperative Group. Eur J Cancer Clin Oncol 1986 0.75
52 High endothelial cell proliferation index and high microvessel density in vascular hotspots suggest an active angiogenic process in human colorectal adenocarcinomas. Angiogenesis Group. Br J Cancer 1996 0.75
53 Microvascular count and prognosis in colorectal cancer. J Clin Oncol 1996 0.75
54 Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. Br J Cancer 1997 0.75
55 Primary mediastinal leiomyosarcoma. Thorac Cardiovasc Surg 1993 0.75
56 5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Cancer 1995 0.75
57 Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. J Cancer Res Clin Oncol 1991 0.75
58 Neoadjuvant and adjuvant therapy for invasive bladder tumors. Eur J Cancer 1991 0.75
59 Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors--an antiangiogenic effect? Anticancer Drugs 1996 0.75
60 Effects and systemic uptake of the new mitomycin C analogue KW-2149 in beagle dogs after intravesical administration. Urol Res 1995 0.75
61 Radiotherapy and chemotherapy in testis tumors. J Belge Radiol 1993 0.75
62 Magnetic resonance imaging of primary malignant bone tumors. Radiographics 1985 0.75
63 Control of anticoagulation in rats. Experientia 1974 0.75
64 KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study. Anticancer Drugs 1999 0.75
65 [Interactions of carboplatin, cisplatin, and ionizing radiation on a human cell line of ovarian cancer]. Cancer Radiother 1999 0.75
66 The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry. Biol Mass Spectrom 1994 0.75
67 Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1989 0.75
68 Late relapse of a non-seminomatous germ cell tumour from residual mature teratoma. Acta Clin Belg 1998 0.75
69 Diagnosis and treatment of soft tissue sarcomas in adults. Curr Opin Oncol 1994 0.75
70 The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts. Anticancer Drugs 1996 0.75
71 Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells. Cancer Immunol Immunother 1993 0.75
72 The management of ovarian cancer. Ann Oncol 1993 0.75
73 Scintigraphic peritoneography in advanced ovarian malignancies: its value for chemotherapeutic distribution studies. Clin Radiol 1984 0.75
74 [In vitro effects of piracetam on the radiosensitivity of hypoxic cells (adaptation of MTT assay to hypoxic conditions)]. Bull Cancer 1995 0.75
75 Comparison of daunorubicin and Fluo-3 for detection of multidrug resistance in human tumor cells. Cancer Detect Prev 1997 0.75
76 Deep cerebral invasion by basal cell carcinoma of the scalp. Neuroradiology 1996 0.75
77 Objective response criteria in phase II and phase III studies. Prog Clin Biol Res 1988 0.75
78 Bioanalysis of suramin in human plasma by ion-pair high-performance liquid chromatography. J Chromatogr 1990 0.75
79 Predictive testing in cancer chemotherapy. I. In vivo. Pharm Weekbl Sci 1985 0.75
80 Cryptorchidism and extragonadal germ cell tumor. Urol Int 1995 0.75